Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.

Expert Comments:

Jason Kolbert, Maxim Group (11/27/15)
"Mesoblast Ltd.'s partner, JCR Pharma, announced that the launch of TEMCELL (formerly Prochymal) for the treatment of acute graft-versus-host disease (aGVHD) following an allogeneic bone marrow transplant is anticipated in Feb. 2016. . .Mesoblast expects a treatment course of TEMCELL in an adult Japanese patient to be reimbursed at ¥13,898,880 (AU$156,000 or $113,000) or up to ¥20,848,320 (AU$234,000 or $170,000). . .in the U.S. the company is enrolling a single-arm, open-label Phase 3 registration trial to support product approval. . .we believe that SC-100IV (Prochymal). . .could be on the market in the next two years as a commercial product in the U.S."

Kevin DeGeeter, Ladenburg Thalmann (11/25/15)
"Mesoblast Ltd. expects to present interim topline Phase 3 data in calendar Q3/16 with complete data from the 60-patient study in calendar H1/17. Whether the company files a biologics license application based on the interim analysis (management's base case) or full data set (our base case), we believe the potential launch of Mesoblast's first significant commercial product should positively alter the investment profile; we believe the program serves a significant unmet need in steroid refractory pediatric cases ($100M+ opportunity) with potential upside in a larger adult population."

Jason Kolbert, Maxim Group (11/25/15)
"Mesoblast Ltd. raised net proceeds of $58M in a U.S. initial public offering. . .we estimate the company now has approximately $136M in cash or 18 months of capital runway with multiple catalysts and events ahead. . .our fundamental analysis has not changed."

Kevin DeGeeter, Ladenburg Thalmann (11/24/15)
"Mesoblast Ltd.'s Phase 2 study is enrolling 48 patients with active rheumatoid arthritis and who failed TNF-alpha therapies. Patients will receive a single infusion of 1 or 2 million MPCs/kg or placebo. . .the company expects to present interim topline Phase 3 acute graft-versus-host disease data in calendar Q3/16 with complete data from the 60-patient study in H1/17."

Henry McCusker, RegMed Investors (11/16/15)
"Mesoblast Ltd. said it expects to raise about $63.8M (CA$95.8M) from the initial public offering, excluding underwriting discounts, commissions and expenses associated with the equity issue. The company will use the proceeds to fund its clinical trial programs, research and development, manufacturing requirements and general administrative expenses. . .the NASDAQ float has brought in enough cash to give Mesoblast '18 months of runway' to fund the final stages of its key clinical trials."

Henry McCusker, RegMed Investors (10/30/15)
"Mesoblast Ltd. announced that it plans to conduct a registered initial public offering in the U.S. under the symbol MESO. . .the company also changed its reporting currency to U.S. dollars from Australian dollars. This change is in line with Mesoblast progressively increasing its proportion of operational expenditure denominated in U.S. dollars resulting from P3 programs currently recruiting across North America."

More Expert Comments

Experts Following This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker RegMed Investors
Henry McCusker, Founder and Director of Research – Scimitar Equity
Alain Vertes, Managing Director – NxR Biotechnologies GmbH
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.